Stocks were boosted in May by easing trade tensions, solid corporate earnings and signs the U.S. economy remains resilient ...

Swiss President Karin Keller-Sutter will visit pharma powerhouse Ireland tomorrow for high-level talks ahead of President ...

Eli Lilly’s acquisition of SiteOne Therapeutics comes ahead of Phase 2 testing of the startup’s lead drug candidate, which ...

Pharmaceutical companies are making billions on treatments that can sometimes overpromise and underdeliver for terminal cases ...

Pharma company stocks tumbled after Donald Trump announced a plan to reduce U.S. drug prices, but regained some ground on belief the plan would be hard to implement Drug prices are expected to decline ...

The supply of GLP-1 drugs has been increasing, but they’re still expensive for most patients. Here are answers to some ...

The deal prepares for a pain treatment market rivalry with Vertex Pharmaceuticals as the industry starts to move away from ...

Eli Lilly will buy privately held SiteOne Therapeutics in a deal worth as much as $1 billion, the companies said on Tuesday, ...

The Trump administration's escalating calls for drug companies to lower prices underscore just how stuck the industry is in ...

President Donald Trump’s proposal to peg US drug prices to those paid abroad includes granting the FDA legal authority to ...

Tariffs on pharmaceutical imports could hurt Lilly, especially with its dependence on products made in Ireland. The president ...

Squeezed by insurers and middlemen, independent pharmacists such as Jolley find themselves on the front lines of a tariff storm. Nearly everyone down the line — drugmakers, pharmacies, wholesalers, ...